Antiaging Effect of Pine Pollen in Human Diploid Fibroblasts and in a Mouse Model Induced by D-Galactose

Table 2

Body weight and AGEs Levels.

Group	Treatment	Body weight		Serum AGEs (ng/mL)	Cerebral AGEs (ng/mg prot)
		Pretreatment	Posttreatment
I	Young control	22.83±1.13	25.32±1.15	145.34±47.73	24.71±23.42
II	D-gal (100 mg/kg)	22.62±0.98	23.93±0.98	294.65±165.93 *	53.46±29.57 *
III	D-gal + PP (500 mg/kg)	22.37±0.80	23.28±1.00	163.47±158.04^▵	31.46±14.86
IV	D-gal + PP (1000 mg/kg)	21.84±0.93	22.99±1.42	201.69±118.65	31.67±18.65
V	D-gal + PP (1500 mg/kg)	22.13±1.46	23.52±1.80	202.08±158.40	27.71±19.06^▵
VI	D-gal + AG (100 mg/kg)	22.32±1.32	24.63±2.05	158.29±101.17^▵	23.88±19.17^▵

Note. C57BL/6J female mice (5-month-old, 𝑛=10 in each group) were treated daily with PBS (s.c, young control), D-galactose (D-gal, 100 mg/kg, s.c), D-gal (100 mg/kg, s.c) with pine pollen (PP, 500, 1000, 1500 mg/kg, ig) and aminoguanidine (AG, 100 mg/kg, ig). AGEs levels at the end of the treatment were determined by a quantitative AGEs-ELISA kit. Statistical significant difference: ^∗𝑃<0.05, versus I; ^▵𝑃<0.05, versus II.